Allied Market Research
Upcoming Allied Market Research
Carfilzomib Market

Carfilzomib Market by Type (10mg Injection, 30mg Injection, and 60mg Injection) and Application (Hospitals, Drug centers, Clinics, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030

Pages: NA
Oct 2021 | 74 Views
Author(s) : Onkar Sumant
Tables: NA
Charts: NA
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.



Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Carfilzomib Market

Request Now !

Carfilzomib, also known as kyprolis, is an anti-cancer medication derived from epoxomicin, which is a naturally occurring product. Epoxomicin is known to inhibit proteasome. Carfilzomib binds to 20-S proteasome and inhibits the chymotrypsin-like activity. It is used in the injection form combined with other drugs such as dexamethasone or lenalidomide to treat people suffering from blood cancer or multiple myeloma that affects plasma cells. Although the drug is highly viable, it still expresses few side effects which include excretion of black stool, blood in the urine, severe bloating, chest pain, and burning. Carfilzomib can be segmented based on type and potency with 10mg injection as the least potent one and 60mg injection with highest potency. Carfilzomib offers various advantages over traditional cancer treatment therapy such as increased efficacy and reduced adverse side effects.

Market Scope and Structure Analysis

Report Metric


 Market Size Available for Years


 Base Year Considered


 Forecast Period


 Forecast Unit

 Value (USD)

 Segments Covered

 Type, Application, and Region

 Regions Covered

 North America, Europe, Asia-Pacific, and LAMEA

 Companies Covered

Cayman Chemical, Tecoland Corporation, Shanghai Chiral Chemicals, Vijayasri organics Ltd, Amgen Inc, Gyma Laboratories of America, Hangzhou Longshine Bio-Tech Co. Ltd., Active Peptide, Natco, AstraZeneca.

COVID-19 Impact Analysis

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the carfilzomib market.

Top Impacting Factors

  • Rise in the number of people suffering from blood cancer in densely populated regions like South Asia and subsequent demand for treatment therapy is a major reason for growth of carfilzomib market.
  • Several advantages of carfilzomib over traditional cancer treatment technique such as increased efficacy and reduced adverse effects as compared to proteasome inhibitor therapy plus reduced hypertension, less chances of cardiac failure, and dyspnea offer huge long-term market gains for carfilzomib.
  • Global market currently has limited number of approved therapies for myeloma treatment, thus providing a huge opportunity to vendors for effective creation of new carfilzomib products under various new potencies. This is anticipated to provide lucrative opportunities for the market.
  • However, lack of awareness and continued apathy combined with misconceptions among population in underdeveloped nations against new age cancer treatment techniques acts as a key restraint of the global market.
  • Additionally, high administration cost and inability of manufacturers to balance out the cost-benefit tradeoff is another factor hampering penetration into tier-3 population base.

Key Market Trends

  • North America is anticipated to hold onto its position as the biggest market for carfilzomib owing to increasing number of blood and bone marrow cancer cases erupting in the region due to certain micro and macro environmental factors.
  • Natco Ltd. recently received approval for administration and selling of 10mg and 60mg strengths of carfilzomib drug. The venture is a collaboration between Natco Ltd. and Creckenridge Pharmaceuticals to market the product in the U.S.
  • Asia-Pacific is witnessing growth in the market due to growing awareness about cancer, its types, and treatment forms such as chemotherapy coupled with rising disposable income and surging demand for advanced therapeutic drugs.
  • Recent clinical trials conducted by Multiple Myeloma Research Consortium showed that single dose of carfilzomib among patients who have received at least 2 prior therapies, including bortezomib and thalidomide and failed has proved quite efficient. An important conclusion was that even patients with baseline neuropathy were able to successfully tolerate carfilzombi single dose without any chances or worsening condition.
  • A recent study by a syndicate firm in the U.S. concluded that administration of carfilzomib combined with thalidomide as an induction therapy in patients with newly discovered multiple myeloma proved highly feasible and effective.
  • Carfilzomib is currently undergoing a multi company initiative known as ASPIRE trials to find out the efficacy and feasibility of using the drug in combination with lenalidomide and low-dose dexamethasone in patients suffering from relapsed multiple myeloma.

Key Segments Covered




  • 10mg Injection
  • 30mg Injection
  •  60mg Injection


  • Hospitals
  •  Drug centers
  •  Clinics
  •  Others


  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Benefits of the Report

  • This study presents the analytical depiction of the Carfilzomib industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
  • The current market is quantitatively analyzed from 2020 to 2030 to highlight the growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Carfilzomib Report

  • Which are the leading players active in the Carfilzomib market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the Carfilzomib market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Start reading ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

Toll-free :
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email :
Allied Market Research Allied Market Research Allied Market Research

Access from any device, anywhere

Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.










Purchase Full Report of
Carfilzomib Market

Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456  $3,110
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,456
  • Restricted to one authorized user
  • One print only
  • Available in
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769  $5,192
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $5,805
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise

  • $9,995  $8,996
  • Unlimited
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
  • Company Profiles
  • Newly Added Content Access
  • 10 PDF
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD


Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers


Featured Reports


Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings


Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers